Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis

Pediatric Nephrology

Volumn 30, Issue 3, 2015, Pages 469-477

  Garin, Eduardo H ^a   Reiser, Jochen ^b   Cara Fuentes, Gabriel ^a   Wei, Changli ^b   Matar, Dany ^c   Wang, Heiman ^a   Alachkar, Nada ^c   Johnson, Richard J ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

CD80; CTLA 4; Focal segmental glomerulosclerosis; Minimal change disease; Nephrotic syndrome

Indexed keywords

ABATACEPT; B7 ANTIGEN; BELATACEPT; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G1; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; ANASARCA; ARTICLE; CASE STUDY; CHILD; CLINICAL ARTICLE; CREATININE URINE LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MINIMAL CHANGE DISEASE; NEPHROTIC SYNDROME; PLASMAPHERESIS; PODOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RELAPSE; SCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; YOUNG ADULT; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; NEPHROSIS, LIPOID; URINE;

ABATACEPT; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CTLA-4 ANTIGEN; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROSIS, LIPOID; YOUNG ADULT;

EID: 84924964566     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2957-6     Document Type: Article

References (28)

1. Habib R, Kleinknecht C (1971) The primary nephrotic syndrome in childhood: Classification and clinicopathologic study of 406 cases. Pathol Annu 6:417–474
2. [No authors listed] (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of kidney Disease in Children. J Pediatr 98:561-564
3. Davison AM, Cameron SJ, Grünfeld JP (2005) Textbook of Clinical Nephrology, 3rd edn. Oxford University Press, New York, pp 439–469
4. Barisoni L, Schnaper HW, Kopp JB (2007) A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2:529–542
5. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260–266
6. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78:296–302
7. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113:1390–1397
8. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883
9. Savin VJ, McCarthy ET, Sharma R, Reddy S, Dong J, Hess S, Kopp J (2008) Cardiotrophin-like cytokine-1: Candidate for the focal glomerulosclerosis permeability factor (abstract). J Am Soc Nephrol 19:59A
10. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55–63
11. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960
12. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet and FSGS CT Study Consortia (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059
13. Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, Lanaspa MA, Rivard C, Maruyama S, Garin EH, Johnson RJ (2013) Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant 28:1439–1446
14. Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH (2011) Minimal Change Disease: A “Two hit” podocyte immune disorder? Pediatr Nephrol 26:645–649
15. International Study of Kidney Disease in Children (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765-771
16. Oaks MK, Hallet KM (2000) Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 164:5015–5018
17. Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D’Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH (2014) Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol 25:1415–1429
18. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561–569
19. Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH (2014) Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol. doi:10.1007/s00467-014-2874-8
20. Spink C, Stege G, Tenbrock K, Harendza S (2013) The CTLA-4 + 49GG genotype is associated with susceptibility for nephrotic kidney diseases. Nephrol Dial Transplant 28:2800–2805
21. Ohl K, Spink C, Wagner N, Zahn K, Wagner N, Eggermann T, Kemper MJ, Querfeld U, Hoppe B, Harendza S, Tenbrock K (2014) CTLA4 polymorphism in minimal change nephrotic syndrome in children: A case-control study. Am J Kidney Dis 63:1074–1075
22. Chang JM, Hwang DY, Chen SC, Kuo MC, Hung CC, Hwang SJ, Tsai JC, Chen HC (2013) B7-1 expression regulates the hypoxia-driven cytoskeleton rearrangement in glomerular podocytes. Am J Physiol Ren Physiol 304:F127–F136
23. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416–2423
24. Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parchoux B, Martin X, David L (1993) Recurrent nephrotic syndrome after transplantation: early treatment with plasmapheresis and cyclophosphamide. Pediatr Nephrol 7:50–54
25. Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ (2003) Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 18:934–938
26. Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, Gaha K, Thervet E, Lefrère F, Cavazzana-Calvo M, Noël LH, Méjean A, Legendre C, Martinez F (2009) Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 9:1081–1086
27. Alachkar N, Carter-Monroe N, Reiser J (2014) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 370:1263–1264
28. Benigni A, Gagliardini E, Remuzzi G (2014) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 370:1261–1263